Return of fertility after use of the injectable contraceptive Depo Provera: up-dated data analysis

J Biosoc Sci. 1984 Jan;16(1):23-34. doi: 10.1017/s0021932000014760.

Abstract

PIP: 796 Thai women who stopped using the long-acting injectable contraceptive depot medroxyprogesterone acetate (DMPA, Depo Povera), 437 women who stopped using oral contraceptives and 125 women who had an IUD removed to have a planned pregnancy, were followed up to ascertain the delay to conception after the end of contraception and to determine the proportion of women who did not conceive in the 4 years after discontinuation. The median delay to conception was 5.5 months plus the estimated duration of the effect of the last injection of DMPA, 3 months for oral contraceptives and 4.5 months after discontinuing the IUD. The proportion of women who did not conceive within 9 months after discontinuation of DMPA is similar to that of ex-IUD users, and by 3 years to that of the ex-pill sample. There is no evidence to suggest that prolonged use of DMPA increases the delay to conception. The return of fertility among never pregnant ex-users resembled that of ever pregnant ex-users. There were comparable proportons of live births among ex-DMPA users and ex-pill users and both of these showed higher proportions of live-births than ex-IUD users. There was no evidence to suggest that previous use of DMPA had any significant adverse effect on the outcome of pregnancy of the subsequent births. This study did not show any association between infertility and the previous use of DMPA or other contraceptives.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Contraceptive Agents, Female / adverse effects*
  • Female
  • Fertility / drug effects
  • Humans
  • Infertility, Female / chemically induced*
  • Medroxyprogesterone / adverse effects
  • Medroxyprogesterone / analogs & derivatives*
  • Medroxyprogesterone Acetate
  • Pregnancy
  • Thailand

Substances

  • Contraceptive Agents, Female
  • Medroxyprogesterone Acetate
  • Medroxyprogesterone